Opioid use disorder

References

Key articles

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.

World Health Organization. International statistical classification of diseases and health related problems (ICD). 11th revision. Jan 2022 [Internet publication].Full text

Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. Mar 2015 [internet publication].Full text

National Institute for Health and Care Excellence. Drug misuse in over 16s: opioid detoxification. Jul 2007 (reaffirmed 2019) [internet publication].Full text

Gowing L, Ali R, White JM, et al. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017 Feb 21;2(2):CD002025.Full text  Abstract

Reference articles

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.

2. World Health Organization. International statistical classification of diseases and health related problems (ICD). 11th revision. Jan 2022 [Internet publication].Full text

3. National Institute on Drug Abuse. Commonly used drugs charts. Aug 2020 [internet publication].Full text

4. United Nations Office on Drugs and Crime. World drug report 2021: drug market trends - cannabis, opioids. Jun 2021 [internet publication].Full text

5. DeWeerdt S. Tracing the US opioid crisis to its roots. Nature. 2019 Sep;573(7773):S10-2.Full text  Abstract

6. Humphreys K, Shover CL, Andrews CM, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022 Feb 5;399(10324):555-604. Abstract

7. Hedegaard H, Miniño AM, Spencer MR, et al; National Center for Health Statistics. NCHS data brief: drug overdose deaths in the United States, 1999–2020. Dec 2021 [internet publication].Full text

8. Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015 Jun 10;350:h2698.Full text  Abstract

9. Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017 Mar 14;356:j760.Full text  Abstract

10. Jeffery MM, Hooten WM, Jena AB, et al. Rates of physician coprescribing of opioids and benzodiazepines after the release of the Centers for Disease Control and Prevention guidelines in 2016. JAMA Netw Open. 2019 Aug 2;2(8):e198325.Full text  Abstract

11. UK Health Security Agency. Shooting up: infections among people who inject drugs in the UK. Feb 2022 [internet publication].Full text

12. Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019 Apr 27;393(10182):1760-72. Abstract

13. Ko JY, D'Angelo DV, Haight SC, et al. Vital signs: prescription opioid pain reliever use during pregnancy - 34 U.S. jurisdictions, 2019. MMWR Morb Mortal Wkly Rep. 2020 Jul 17;69(28):897-903.Full text  Abstract

14. Bateman BT, Hernandez-Diaz S, Straub L, et al. Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. BMJ. 2021 Feb 10;372:n102.Full text  Abstract

15. Latkin CA, Mandell W, Vlahov D, et al. The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE study. Am J Community Psychol. 1996 Jun;24(3):341-64. Abstract

16. Neaigus A, Miller M, Friedman SR, et al. Potential risk factors for the transition to injecting among non-injecting heroin users: a comparison of former injectors and never injectors. Addiction. 2001 Jun;96(6):847-60. Abstract

17. Callaly T, Trauer T, Munro L, et al. Prevalence of psychiatric disorder in a methadone maintenance population. Aust N Z J Psychiatry. 2001 Oct;35(5):601-5. Abstract

18. Krausz M, Degkwitz P, Kuhne A, et al. Comorbidity of opiate dependence and mental disorders. Addict Behav. 1998 Nov-Dec;23(6):767-83. Abstract

19. Milby JB, Sims MK, Khuder S, et al. Psychiatric comorbidity: prevalence in methadone maintenance treatment. Am J Drug Alcohol Abuse. 1996 Feb;22(1):95-107. Abstract

20. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990 Nov 21;264(19):2511-8. Abstract

21. Klimas J, Gorfinkel L, Fairbairn N, et al. Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: a systematic review. JAMA Netw Open. 2019 May 3;2(5):e193365.Full text  Abstract

22. Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021 May 19;373:n784. Abstract

23. Crist RC, Reiner BC, Berrettini WH. A review of opioid addiction genetics. Curr Opin Psychol. 2019 Jun;27:31-5.Full text  Abstract

24. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002 Jul;1(1):13-20.Full text  Abstract

25. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001 Feb;24(2):97-129.Full text  Abstract

26. Dawe S, Gray JA. Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug Alcohol Depend. 1995 Oct;39(3):207-12. Abstract

27. Campbell G, Noghrehchi F, Nielsen S, et al. Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: findings from a 5-year prospective cohort study. EClinicalMedicine. 2020 Nov;28:100592.Full text  Abstract

28. Substance Abuse and Mental Health Services Administration; Department of Health and Human Services. Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health. Oct 2021 [internet publication].Full text

29. Shanahan L, Hill SN, Bechtiger L, et al. Prevalence and childhood precursors of opioid use in the early decades of life. JAMA Pediatr. 2021 Mar 1;175(3):276-85.Full text  Abstract

30. Wilton J, Abdia Y, Chong M, et al. Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study. BMJ. 2021 Nov 18;375:e066965.Full text  Abstract

31. Davis MA, Lin LA, Liu H, et al. Prescription opioid use among adults with mental health disorders in the United States. J Am Board Fam Med. 2017 Jul-Aug;30(4):407-17.Full text  Abstract

32. Edlund MJ, Steffick D, Hudson T, et al. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007 Jun;129(3):355-62. Abstract

33. Santo T Jr, Campbell G, Gisev N, et al. Exposure to childhood trauma increases risk of opioid use disorder among people prescribed opioids for chronic non-cancer pain. Drug Alcohol Depend. 2022 Jan 1;230:109199. Abstract

34. Fortson K, Rajbhandari-Thapa J, Ingels J, et al. Adverse childhood experiences, risk of opioid misuse and its pathway among students at a public university. J Am Coll Health. 2021 Nov 17:1-10. Abstract

35. Guarino H, Mateu-Gelabert P, Quinn K, et al. Adverse childhood experiences predict early initiation of opioid use behaviors. Front Sociol. 2021 May 13;6:620395.Full text  Abstract

36. Griesler PC, Hu MC, Wall MM, et al. Assessment of prescription opioid medical use and misuse among parents and their adolescent offspring in the US. JAMA Netw Open. 2021 Jan 4;4(1):e2031073.Full text  Abstract

37. Dowell D, Ragan KR, Jones CM, et al. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022 Nov 4;71(3):1-95.Full text  Abstract

38. Compton WM, Jones CM, Baldwin GT, et al. Targeting youth to prevent later substance use disorder: an underutilized response to the US opioid crisis. Am J Public Health. 2019 Jun;109(s3):S185-9.Full text  Abstract

39. Mitchell C, Dolan N, Dürsteler KM. Management of dependent use of illicit opioids. BMJ. 2020 Mar 9;368:m710. Abstract

40. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020 Jun 20;395(10241):1938-48.Full text  Abstract

41. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980 Jan;168(1):26-33. Abstract

42. Substance Abuse and Mental Health Services Administration. Clinical drug testing in primary care: technical assistance publication series TAP 32. 2012 [internet publication].Full text

43. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008 Jan;83(1):66-76.Full text  Abstract

44. Mayo Clinic Laboratories. Methadone [internet publication].Full text

45. American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. 2020 Mar/Apr;14(2S suppl 1):1-91.Full text  Abstract

46. US Preventive Services Task Force. Unhealthy drug use: screening. Jun 2020 [internet publication].Full text

47. Hickman M, Lingford-Hughes A, Bailey C, et al. Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction. 2008 Jul;103(7):1060-2. Abstract

48. Zacny JP, Lichtor SA. Nonmedical use of prescription opioids: motive and ubiquity issues. J Pain. 2008 Jun;9(6):473-86.Full text  Abstract

49. Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Internal Med. 2010 Jun 1;152(11):712-20. Abstract

50. American College of Obstetricians and Gynecologists. Opioid use and opioid use disorder in pregnancy. Committee Opinion No 711. Aug 2017 (reaffirmed 2021) [internet publication].Full text

51. Ecker J, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol. 2019 Jul;221(1):B5-28.Full text  Abstract

52. Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014 Jul;30(7):557-64.Full text  Abstract

53. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 (20 suppl):22-33;quiz 34-57. Abstract

54. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat. 2007 Mar;32(2):189-98. Abstract

55. Rosenberg SD, Drake RE, Wolford GL, et al. Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. Am J Psychiatry. 1998 Feb;155(2):232-8. Abstract

56. Wickersham JA, Azar MM, Cannon CM, et al. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care. 2015 Jan;21(1):12-26.Full text  Abstract

57. Rieb LM, Samaan Z, Furlan AD, et al. Canadian guidelines on opioid use disorder among older adults. Can Geriatr J. 2020 Mar;23(1):123-34.Full text  Abstract

58. National Institute on Drug Abuse. Principles of drug addiction treatment: a research based guide. 3rd ed. Jan 2018 [internet publication].Full text

59. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO Press; 2009.Full text

60. Brecht ML, Hser YI, Anglin MD. A multimethod assessment of social intervention effects on narcotics use and property crime. Int J Addict. 1990-1991;25(11A):1317-40. Abstract

61. Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. Mar 2015 [internet publication].Full text

62. Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse. 2011 Jan;37(1):1-11. Abstract

63. Mee-Lee D, Shulman GD, Fishman MJ, et al., (eds). The ASAM Criteria: treatment criteria for addictive, substance-related, and co-occurring conditions. 3rd ed. Carson City, NY: The Change Companies; 2013.

64. Galanter M, Kleber HD, eds. The American Psychiatric Publishing textbook of substance abuse treatment. Washington, DC: American Psychiatric Publishing; 2008.

65. National Institute for Health and Care Excellence. Drug misuse in over 16s: opioid detoxification. Jul 2007 (reaffirmed 2019) [internet publication].Full text

66. Gowing L, Farrell M, Ali R, et al. Alpha₂-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016 May 3;2016(5):CD002024.Full text  Abstract

67. American College of Emergency Physicians Clinical Policies Subcommittee (writing committee) on opioids; Hatten BW, Cantrill SV, et al. Clinical policy: critical issues related to opioids in adult patients presenting to the emergency department. Ann Emerg Med. 2020 Sep;76(3):e13-39.Full text  Abstract

68. Santo T Jr, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Sep 1;78(9):979-93.Full text  Abstract

69. US Department of Veterans Affairs; Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. Aug 2021 [internet publication].Full text

70. Zubieta J, Greenwald MK, Lombardi U, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 2000 Sep;23(3):326-34.Full text  Abstract

71. Blazes CK, Morrow JD. Reconsidering the usefulness of adding naloxone to buprenorphine. Front Psychiatry. 2020 Sep 11;11:549272.Full text  Abstract

72. Gowing L, Ali R, White JM, et al. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017 Feb 21;2(2):CD002025.Full text  Abstract

73. Johnson RE, Fudala PJ, Jaffe JH. Outpatient comparison of buprenorphine and methadone maintenance. I. Effects on opiate use and self-reported adverse effects and withdrawal symptomatology. NIDA Res Monogr. 1990;105:585-6. Abstract

74. Fudala PJ, Johnson RE, Jaffe JH. Outpatient comparison of buprenorphine and methadone maintenance. II. Effects on cocaine usage, retention time in study and missed clinic visits. NIDA Res Monogr. 1990;105:587-8. Abstract

75. Johnson RE, McCagh JC. Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep. 2000 Dec;2(6):519-26. Abstract

76. Amato L, Davoli M, Minozzi S, et al. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD003409.Full text  Abstract

77. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust. 1999 Feb 1;170(3):104-9.Full text  Abstract

78. Kleber HD, Topazian M, Gaspari J, et al. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse. 1987;13(1-2):1-17. Abstract

79. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict. 1988 May;83(5):567-75. Abstract

80. Meader N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend. 2010 Apr 1;108(1-2):110-4. Abstract

81. Huybrechts KF, Hernández-Díaz S, Straub L, et al. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA. 2018 Dec 18;320(23):2429-37.Full text  Abstract

82. Royal College of Obstetricians and Gynaecologists. Management of nausea and vomiting of pregnancy and hyperemesis gravidarum: green-top guideline no. 69. Jun 2016 [internet publication].Full text

83. Medicines and Healthcare products Regulatory Agency. Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy. Jan 2020 [internet publication].Full text

84. Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD005031.Full text  Abstract

85. Broome KM, Joe GW, Simpson DD. HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences. AIDS Educ Prev. 1999 Aug;11(4):293-306. Abstract

86. Longshore D, Hsieh S. Drug abuse treatment and risky sex: evidence for a cumulative treatment effect? Am J Drug Alcohol Abuse. 1998 Aug;24(3):439-51. Abstract

87. Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016 May 9;(5):CD011117.Full text  Abstract

88. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb 6;(2):CD002207.Full text  Abstract

89. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr 26;357:j1550.Full text  Abstract

90. Bruneau J, Ahamad K, Goyer MÈ, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018 Mar 5;190(9):E247-57.Full text  Abstract

91. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003 Sep 4;349(10):949-58.Full text  Abstract

92. Schottenfeld RS, Pakes J, O'Connor P, et al. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry. 2000 Jun 15;47(12):1072-9. Abstract

93. Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018 Jun 1;178(6):764-73. Abstract

94. Breen CL, Harris SJ, Lintzeris N, et al. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend. 2003 Jul 20;71(1):49-55. Abstract

95. Clark N, Lintzeris N, et al. Transferring from high doses of methadone to buprenorphine: a randomized trial of three different buprenorphine schedules. Presented at College on the Problems of Drug Dependence. Scottsdale, AZ; Jun 2006.

96. National Institute for Health and Care Excellence. Methadone and buprenorphine for the management of opioid dependence. Jan 2007 (reaffirmed Feb 2016) [internet publication].Full text

97. Zhang P, Tossone K, Ashmead R, et al. Examining differences in retention on medication for opioid use disorder: an analysis of Ohio Medicaid data. J Subst Abuse Treat. 2022 May;136:108686. Abstract

98. Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psychiatry. 1984 Sep;45(9 Pt 2):39-41. Abstract

99. Washton AM, Gold MS, Pottash AC. Successful use of naltrexone in addicted physicians and business executives. Adv Alcohol Subst Abuse. 1984 Winter;4(2):89-96. Abstract

100. Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat. 1997 Jan-Feb;14(1):19-22. Abstract

101. Brahen LS, Henderson RK, Capone T, et al. Naltrexone treatment in a jail work-release program. J Clin Psychiatry. 1984 Sep;45(9 pt 2):49-52. Abstract

102. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011 Apr 13;2011(4):CD001333.Full text  Abstract

103. Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011 Apr 30;377(9776):1506-13.Full text  Abstract

104. Syed YY, Keating GM. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs. 2013 Oct;27(10):851-61. Abstract

105. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016 Mar 31;374(13):1232-42.Full text  Abstract

106. Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs. 2012 Nov;73(6):991-7. Abstract

107. Tanum L, Solli KK, Latif ZE, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017 Dec 1;74(12):1197-205.Full text  Abstract

108. Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018 Jan 27;391(10118):309-18.Full text  Abstract

109. Woody GE, McLellan AT, Luborsky L, et al. Psychotherapy in community methadone programs: a validation study. Am J Psychiatry. 1995 Sep;152(9):1302-8. Abstract

110. Dugosh K, Abraham A, Seymour B, et al. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016 Mar-Apr;10(2):93-103.Full text  Abstract

111. Hruschak V, Cochran G, Wasan AD. Psychosocial interventions for chronic pain and comorbid prescription opioid use disorders: a narrative review of the literature. J Opioid Manag. 2018 Sep/Oct;14(5):345-58. Abstract

112. Avery N, McNeilage AG, Stanaway F, et al. Efficacy of interventions to reduce long term opioid treatment for chronic non-cancer pain: systematic review and meta-analysis. BMJ. 2022 Apr 4;377:e066375.Full text  Abstract

113. Garland EL, Hanley AW, Nakamura Y, et al. Mindfulness-oriented recovery enhancement vs supportive group therapy for co-occurring opioid misuse and chronic pain in primary care: a randomized clinical trial. JAMA Intern Med. 2022 Apr 1;182(4):407-17.Full text  Abstract

114. McGovern R, Newham JJ, Addison MT, et al. Effectiveness of psychosocial interventions for reducing parental substance misuse. Cochrane Database Syst Rev. 2021 Mar 16;3(3):CD012823.Full text  Abstract

115. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005 Oct;62(10):1157-64.Full text  Abstract

116. Woody GE, Poole SA, Subramaniam G, et al. Extended vs. short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008 Nov 5;300(17):2003-11.Full text  Abstract

117. Feillin DA. Treatment of adolescent opioid dependence: no quick fix. JAMA. 2008 Nov 5;300(17):2057-9. Abstract

118. Hopfer CJ, Khuri E, Crowley TJ, et al. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat. 2002 Oct;23(3):231-37. Abstract

119. Marsch LA. Treatment of adolescents. In: Strain EC, Stitzer ML, eds. The treatment of opioid dependence. Baltimore, MD: Johns Hopkins University Press; 2005:497-507.

120. Dattel BJ. Substance abuse in pregnancy. Semin Perinatol. 1990 Apr;14(2):179-87. Abstract

121. World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. 2014 [internet publication].Full text

122. Terplan M, Laird HJ, Hand DJ, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. 2018 May;131(5):803-14.Full text  Abstract

123. Brown HL, Britton KA, Mahaffey D, et al. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol. 1998 Aug;179(2):459-63. Abstract

124. Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants borne to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006 May 20;82(3):250-7. Abstract

125. Schindler SD, Eder H, Ortner R, et al. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2003 Jan;98(1):103-10. Abstract

126. Hytinantti T, Kahila H, Renlund M, et al. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Pediatr. 2008 Aug;97(8):1040-4. Abstract

127. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008 Jul 1;96(1-2):69-78. Abstract

128. Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med. 2015 Apr;10(3):135-41. Abstract

129. Link HM, Jones H, Miller L, et al. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. Am J Obstet Gynecol MFM. 2020 Aug;2(3):100179. Abstract

130. Minozzi S, Amato L, Jahanfar S, et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD006318.Full text  Abstract

131. Amass L, Bickel WK, Higgins ST, et al. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994;13(3):33-45. Abstract

132. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005 Aug;100(8):1090-100.Full text  Abstract

133. Novick DM, Kreek MJ, Fanizza AM, et al. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981 Sep;30(3):353-62. Abstract

134. Kreek MJ, Schecter AJ, Gutjahr CL, et al. Methadone use in patients with chronic renal disease. Drug Alcohol Depend. 1980 Mar;5(3):197-205. Abstract

135. Dashe JS, Jackson GL, Olscher DA, et al. Opioid detoxification in pregnancy. Obstet Gynecol. 1998 Nov;92(5):854-8. Abstract

136. McCarthy JJ, Leamon MH, Stenson G, et al. Outcomes of neonates conceived on methadone maintenance therapy. J Subst Abuse Treat. 2008 Sep;35(2):202-6. Abstract

137. Weiss RDP, Potter JS, Provost SE, et al. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemp Clin Trials. 2010 Mar;31(2):189-99.Full text  Abstract

138. Flynn PM, Joe GW, Broome KM, et al. Recovery from opioid addiction in DATOS. J Subst Abuse Treat. 2003 Oct;25(3):177-86. Abstract

139. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993 Apr 21;269(15):1953-9. Abstract

140. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006 Jul 27;355(4):365-74.Full text  Abstract

141. Fareed A, Casarella J, Amar R, et al. Methadone maintenance dosing guideline for opioid dependence, a literature review. J Addict Dis. 2010 Jan;29(1):1-14. Abstract

142. Fareed A, Vayalapalli S, Stout S, et al. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis. 2011 Jan;30(1):27-38. Abstract

143. Rea F, Bell JR, Young MR, et al. A randomized, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend. 2004 Jul 15;75(1):79-88. Abstract

144. Gish EC, Miller JL, Honey BL, et al. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother. 2010 Feb;44(2):343-51. Abstract

145. O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998 Jan 21;279(3):229-34. Abstract

146. Gowing L, Ali R, White JM. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD002022.Full text  Abstract

147. Robertson JR, Raab GM, Bruce M, et al. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial. Addiction. 2006 Dec;101(12):1752-9. Abstract

148. Carney T, Van Hout MC, Norman I, et al. Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders. Cochrane Database Syst Rev. 2020 Feb 18;2(2):CD012254.Full text  Abstract

149. Oviedo-Joekes E, March JC, Romero M, et al. The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. Drug Alcohol Rev. 2010 Jan;29(1):75-80. Abstract

150. Oviedo-Joekes E, Guh D, Brissette S, et al. Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug Alcohol Depend. 2010 Sep 1;111(1-2):50-7. Abstract

151. Karow A, Reimer J, Schäfer I, et al. Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend. 2010 Dec 1;112(3):209-15. Abstract

152. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD003410.Full text  Abstract

153. Canadian Research Initiative in Substance Misuse. National injectable opioid agonist treatment for opioid use disorder clinical guideline. Sep 2019 [internet publication].Full text

154. Miranda A, Taca A. Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment. Am J Drug Alcohol Abuse. 2018;44(1):56-63.Full text  Abstract

155. Beck T, Haasen C, Verthein U, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction. 2014 Apr;109(4):617-26.Full text  Abstract

156. Hämmig R, Köhler W, Bonorden-Kleij K, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014 Oct;47(4):275-81. Abstract

157. Klimas J, Gorfinkel L, Giacomuzzi SM, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open. 2019 Apr 2;9(4):e025799.Full text  Abstract

158. Lehmann K, Kuhn S, Baschirotto C, et al. Substitution treatment for opioid dependence with slow-release oral morphine: retention rate, health status, and substance use after switching to morphine. J Subst Abuse Treat. 2021 Aug;127:108350. Abstract

159. Dunn KE, Tompkins DA, Bigelow GE, et al. Efficacy of tramadol extended-release for opioid withdrawal: a randomized clinical trial. JAMA Psychiatry. 2017 Sep 1;74(9):885-93.Full text  Abstract

160. European Monitoring Centre for Drugs and Drug Addiction. How can contingency management support treatment for substance use disorders? A systematic review. 2016 [internet publication].Full text

161. Bolívar HA, Klemperer EM, Coleman SRM, et al. Contingency management for patients receiving medication for opioid use disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Oct 1;78(10):1092-102.Full text  Abstract

162. Powell VD, Rosenberg JM, Yaganti A, et al. Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review. JAMA Netw Open. 2021 Sep 1;4(9):e2124152.Full text  Abstract

163. Substance Abuse and Mental Health Services Administration. TIP 63: medications for opioid use disorder. Jul 2021 [internet publication].Full text

164. Fairbairn N, Ross J, Trew M, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019 Sep 23;191(38):E1049-56.Full text  Abstract

165. Canadian Research Initiative in Substance Misuse. CRISM national guideline for the clinical management of opioid use disorder. 2018 [internet publication].Full text

166. Canadian Centre on Substance Use and Addiction. Best practices across the continuum of care for the treatment of opioid use disorder. Aug 2018 [internet publication].Full text

167. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic non-cancer pain. May 2017. CMAJ. 2017 May 8;189(18):E659-6.Full text  Abstract

168. Larney S, Tran LT, Leung J, et al. All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis. JAMA Psychiatry. 2020 May 1;77(5):493-502.Full text  Abstract

169. McLellan AT, Luborsky L, Woody GE, et al. Predicting response to alcohol and drug abuse treatments: role of psychiatric severity. Arch Gen Psychiatry. 1983 Jun;40(6):620-5. Abstract

170. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000 Oct 4;284(13):1689-95. Abstract

171. Osterwalder JJ. Naloxone - for intoxications with intravenous heroin and heroin mixtures - harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol. 1996;34(4):409-16. Abstract

172. Berlot G, Gullo A, Romano E, et al. Naloxone in cardiorespiratory arrest. Anaesthesia. 1985 Aug;40(8):819. Abstract

173. Mills CA, Flacke JW, Flacke WE, et al. Narcotic reversal in hypercapnic dogs: comparison of naloxone and nalbuphine. Can J Anaesth. 1990 Mar;37(2):238-44. Abstract

174. Stork CM, Redd JT, Fine K, et al. Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate - a case report. J Toxicol Clin Toxicol. 1995;33(2):179-83. Abstract

175. Sporer KA. Acute heroin overdose. Ann Intern Med. 1999 Apr 6;130(7):584-90. Abstract

176. Surgeon General. Surgeon General’s advisory on naloxone and opioid overdose. Apr 2022 [internet publication].Full text

177. Keen C, Kinner SA, Young JT, et al. Periods of altered risk for non-fatal drug overdose: a self-controlled case series. Lancet Public Health. 2021 Apr;6(4):e249-59.Full text  Abstract

178. Centers for Disease Control and Prevention; US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update: a clinical practice guideline. 2021 [internet publication].Full text

179. Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):229-33.Full text  Abstract

180. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics. 1998 Jun;101(6):1079-88. Abstract

181. Finnegan LP, Connaughton JF Jr, Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1-2):141-58. Abstract

182. Patrick SW, Barfield WD, Poindexter BB, et al. Neonatal opioid withdrawal syndrome. Pediatrics. 2020 Nov;146(5):e2020029074.Full text  Abstract

183. Zankl A, Martin J, Davey JG, et al. Sedatives for opioid withdrawal in newborn infants. Cochrane Database Syst Rev. 2021 May 18;5:CD002053.Full text  Abstract

184. Zankl A, Martin J, Davey JG, et al. Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database Syst Rev. 2021 Jul 7;7(7):CD002059.Full text  Abstract

185. Kraft WK, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008 Sep;122(3):e601-7. Abstract

186. Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. N Engl J Med. 2017 Jun 15;376(24):2341-8.Full text  Abstract

187. de Vries F, Bruin M, Lobatto DJ, et al. Opioids and their endocrine effects: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020 Mar 1;105(3):1020-9.Full text  Abstract

188. Jarvis M, Williams J, Hurford M, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017 May/Jun;11(3):163-73.Full text  Abstract

189. Medicines and Healthcare products Regulatory Agency. Evidence of harm from fentanyl-contaminated heroin. Apr 2017 [internet publication].Full text

190. Lyndon A, Audrey S, Wells C, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017 Sep;112(9):1580-89.Full text  Abstract

191. Horsfall JT, Sprague JE. The pharmacology and toxicology of the 'holy trinity'. Basic Clin Pharmacol Toxicol. 2017 Feb;120(2):115-9.Full text  Abstract

192. Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017 Oct;14(10):e1002396.Full text  Abstract

193. Fry C, Dietze P, Crofts N. Naloxone distribution: remembering hepatitis C transmission as an issue. Addiction. 2000 Dec;95(12):1865-6. Abstract

194. Fischer B, Hayden B, Rehm J, et al. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach: the case study of Canada. J. Urban Health. 2004 Sep;81(3):428-47.Full text  Abstract

195. Torbenson M, Kannangai R, Astemborski J, et al. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology. 2004 Jan;39(1):51-7. Abstract

196. Coppola RC, Manconi PE, Piro R, et al. HCV, HIV, HBV, and HDV infections in intravenous drug addicts. Eur J Epidemiol. 1994 Jun;10(3):279-83. Abstract

Use of this content is subject to our disclaimer